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Fibrodysplasia ossificans progressiva (FOP) is an exceptionally rare genetic disease that is characterised by congenital malforma-
tions of the great toes and progressive heterotopic ossification (HO) in specific anatomical areas.This disease is caused by amutation
in activin receptor IA/activin-like kinase-2 (ACVR1/ALK2). A Mexican family with one member affected by FOP was studied.The
patient is a 19-year-old female who first presented with symptoms of FOP at 8 years old; she developed spontaneous and painful
swelling of the right scapular area accompanied by functional limitation of movement. Mutation analysis was performed in which
genomic DNA as PCR amplified using primers flanking exons 4 and 6, and PCR products were digested with Cac8I and HphI
restriction enzymes.Themost informative results were obtainedwith the exon 4 flanking primers and theCac8I restriction enzyme,
which generated a 253 bp product that carries the ACVR1 617G>Amutation, which causes an amino acid substitution of histidine
for arginine at position 206 of the glycine-serine (GS) domain, and its mutation results in the dysregulation of bone morphogenetic
protein (BMP) signalling that causes FOP.
1. Introduction
Bone morphogenetic protein (BMP) is a highly conserved
molecule that regulates the BMP receptor signalling path-
way and plays an important role in morphogenesis during
vertebrate development and in adults [1]. There are two
serine/threonine kinase type BMP receptors, both of which
have similar functional glycine-serine (GS) domains that are
critical for signal transduction. ACVR1/ALK2 is a type I
receptor that is expressed in many tissues, including skeletal
muscles and chondrocytes. The constitutive activation of
ACVR1/ALK2 induces alkaline phosphatase activity inC2C12
inmortal line of mouse skeletal myoblasts cells, resulting in
the upregulation of BMP4 and the downregulation of BMP
antagonists. ACVR1/ALK2 is an activin-like kinase and is
one of the six activin kinase genes that encode transforming
growth factor-beta (TGF-𝛽)/BMP type I serine/threonine
transmembrane receptors, all of which are involved in cell fate
and differentiation. In patients with fibrodysplasia ossificans
progressiva (FOP), the mutated ACVR1/ALK2 receptor is
hyperactive, which results in the expansion of cartilaginous
elements and ectopic chondrogenesis and promotes joint
ankylosis. FOP is caused by a heterozygous missense acti-
vating mutation (c.617G>A; R206H) that affects the glycine-
serine (GS) activation domain of ACVR1, which is essential
for signal transduction [2, 3], but it is not the only mutation.
We present the clinical and genetic analysis of a patient with
FOP.
2. Case Presentation
A Mexican family with one member affected by FOP was
studied. The patient was a 19-year-old female. Her mother
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Figure 1: Clinical photograph. (a) Heterotopic ossification of the right scapular area, which functionally limited patient movement. Note
the presence of pseudotumours of soft tissue at different locations in the back. (b) Column radiography showing abnormal calcification and
“pseudoexostosis” indicating ligament ossification at the site of attachment. (c) Right forearm with cubit exostoses dependent on ligaments
and aponeuroses. (d) Congenital malformations of the great toes. (e) Radiography of the right scapula and (f) right elbow shows abnormal
calcification dependent on ligament ossification.
stated that the patient exhibited malformation of the great
toes at birth. At the age of 8, the patient developed sponta-
neous and painful swelling in the right scapular area accom-
panied by a functional limitation of movement; her clinical
laboratory abnormalities included increased serum alkaline
phosphatase activity. Radiography demonstrated abnormal
calcification and “pseudoexostosis” that was dependent on
ligament ossification at the site of attachment to the long
bones (Figure 1).
3. Mutation Analysis
ACVR1 617G>A mutation analysis was carried out with
genomic DNA obtained from peripheral blood lymphocytes
using DNAzol (GIBCO-BRL). Total genomic DNA was
used as a template for PCR amplification (Select Cycler,
Bio Products) with the following exon flanking primers:
exon 4 forward 5󸀠-CCA GTC CTT CTT CCT TCT TCC-
3󸀠 and reverse 5󸀠-AGC AGA TTT TCC AAG TTC CAT
C-3󸀠; exon 6 forward 5󸀠-GAC ATT TAC TGT GTA GGT
CGC-3󸀠 and reverse 5󸀠-AGA GAT GCA ACT CAC CTA
ACC-3󸀠 and previously reported PCR conditions [2]. After
amplification, the PCR products were digested with Cac8I
and HphI restriction enzymes (New England Biolabs) for 1 h
at 37∘C and then submitted to 3% agarose gel electrophoresis.
The undigested PCR products were prepared for sequencing
using ultraclean PCR columns, in which a silica membrane
assembly binds the DNA and allows the removal of primers,
nucleotides, and enzymes.The purified PCRproducts of exon
4 were sequenced using the aforementioned primers in a
genetic analyser (Applied Biosystems 3130 xl) that uses cap-
illary electrophoresis and the ChromasPro v. 1.5 software for
analysis.The sequences from the FOP patient were compared
with those of her parents and unrelated healthy controls.
4. Ethics Considerations
The clinical investigation was conducted according to the
principles of the Declaration of Helsinki and was approved
by the ethics committee of our institution. Written informed
consent for genetic testing was obtained from the patient, her
relatives, and controls.
5. Results
PCR amplicons with primers specific to exon 4 produced
similar 350 bp products in controls, relatives, and the
FOP patient; however, Cac8I restriction digestion analysis
produced a 253 bp fragment in the FOP patient only, and
digestion with HphI produced an exclusive FOP fragment
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Figure 2: Genotyping in top panel: PCR amplification products were resolved by 3% agarose gel electrophoresis (C: control, M: mother, F:
father, and P: FOP patient). As shown on the left, similar 350 bp products were amplified in controls, relatives, and the FOP case; however,
after Cac8I digestion, a 253 bp fragment was observed exclusively in the FOP patient (marked with arrow). Bottom panel: a chromatogram
showing the typical mutation at position 617, which causes an amino acid substitution of histidine for arginine at position 206 in the GS
domain of ACVR1/ALK2.
of 228 bp. The 253 bp Cac8I fragment was positive for the
R206H (617G>A) mutation in exon 4 of the ACVR1 gene.
The PCR analysis of exon 6 was negative for any mutation.
Alignment of this sequence confirmed the ACVR1 617 muta-
tion in our patient. This abnormality alters residue 206 of the
protein such that an arginine is substituted by histidine. This
change results in the dysregulation of BMP signalling. This
case was classified as a de novomutation because the ACVR1
206mutation was not present in either of the patient’s parents
(Figure 2).
6. Discussion
AMexican family with one member affected by spontaneous
FOP was studied. The patient was a 19-year-old female when
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this molecular study was conducted; however, her first symp-
toms appeared at the age of 8. The patient exhibited clinical
manifestations of repeated painful soft tissue inflammation
andflare-ups, followed by progressive functional limitation in
joint mobility.The patient was clinically diagnosed with FOP
at the age of 10 and was treated with corticoids. The disease
progression was not modified by this therapy. The patient
lives in an isolated farming community and was referred to
us by an orthopaedic surgeon for an opinion on whether
to excise the bone exostoses. After clinical evaluation, the
patient was informed about the difficulty of performing
any surgery related to new bone formation and received
counselling from the Center for Research in FOP and
Related Disorders at the University of Pennsylvania School of
Medicine in Philadelphia, PA, USA, through the guidelines
of the international FOP consortium. This case was further
studied with routine clinical laboratory and radiographic
analyses, and the underlying molecular abnormality was
defined and subsequently confirmed by genomic analysis in
our laboratory, disclosing a mutation in her ACVR1/ALK2
gene.
Fibrodysplasia ossificans progressiva is clinically charac-
terised by malformations of the great toes and progressive
heterotopic ossification [4]. The great toe malformations are
a unique marker of this disease at birth; other symptoms
appear within the first decade of life. In the reported case,
as in the majority of FOP patients, the patient developed
recurrent painful swelling of the soft tissue and inflam-
matory flare-ups, followed by the ossification of ligaments,
tendons, skeletal muscles, and other soft tissues. FOP patients
frequently develop a breastplate-like armour in the chest;
this phenomenon caused some recurrent pneumonia in our
patient [5, 6].
FOP is extremely rare, occurring in only one of every 2
million people [7]. In Mexico, little is known about this dis-
ease, and this particular clinical case gave us the opportunity
to establish a molecular protocol for studying patients with
this singular disease.
Seminal studies of FOP by Kaplan et al. allowed a better
understanding of FOP. These investigators characterised this
enigmatic disease at the clinical, genetic, and molecular
levels. They discovered that the ACVR1 617G>A mutation
is responsible for the abnormalities observed in FOP. In
addition, their contributions provided a better description
of the roles of ACVR and BMP in bone formation. More
recently, other mutations in the GS domain and kinase
domain of ACVR1 have been described; these mutations are
associated with atypical manifestations of FOP [8].
During FOP flare-ups, inflammation is mediated by
macrophages, lymphocytes, and mast cells, which release
granules that induce oedema in the involved muscles and
ligaments. These events are followed by fibrogenesis and
angiogenesis, which ultimately lead to ossification [9]. The
pathophysiology of the inflammation in FOP seems to be
related to the BMPbinding that induces heteromeric complex
formation by the type I and II BMP receptors.This clustering
is followed by the transduction of downstream signals,
including the Smad proteins, which in turn upregulate the
transcription of target genes involved in inflammation, such
as TNF, IL-1, IL-6, iNOS, chemokines, and other molecules
[10–12].
Although there is no specific treatment for FOP, ther-
apies aiming at reducing inflammatory flare-ups may help
to improve patient quality of life by maintaining as much
residual joint and muscle function as possible [13]. The
use of corticosteroids for short periods during flare-ups
improves symptoms, although animal models have shown
that corticosteroids relieve inflammation but do not inhibit
bone formation [14]. The use of bisphosphonates has been
suggested as a potential therapeutic approach. Other new
molecules may be able to block basic fibroblast growth factor
and selectively block the BMP signalling pathway but are not
yet available for clinical use [13].
In conclusion, we report a typical case of FOP with de
novo ACVR1 mutation. To the best of our knowledge, this is
the first FOP case to be genetically characterised in Mexico.
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